Borges SR, Ramón ME, Díaz DD, Santiesteban PW

Idioma: Español
Referencias bibliográficas: 23
Paginas: 95-106
Archivo PDF: 94.94 Kb.

RESUMEN

El síndrome de vejiga hiperactiva es una condición que afecta la calidad de vida del 17% de las mujeres a nivel mundial, cifra que pudiera elevarse cuando acompaña a los prolapsos de los órganos pélvicos. Múltiples afecciones pueden desencadenar un síndrome de vejiga hiperactiva, aspecto esencial para lograr la efectividad en el diagnóstico y tratamiento de la entidad. Se realizó una revisión sobre el manejo del síndrome de vejiga hiperactiva, en la cual los autores proporcionan una visión general y discuten el tratamiento conservador, farmacológico y quirúrgico disponible, así como las herramientas para definir los principales síntomas y signos de la entidad en pacientes con prolapsos de los órganos pélvicos. Se hace énfasis en el valor de la urodinamia para el diagnóstico y la evolución de las pacientes. Las evidencias científicas revisadas plantean que la urodinamia y la terapia farmacológica juegan un papel importante en los pacientes con síndrome de vejiga hiperactiva y prolapso de los órganos pélvicos, la misma debe ser usada en unión a otras formas conservadoras de tratamiento o al tratamiento quirúrgico, este último no debe ser realizado sin una valoración multidisciplinaria.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Fayyad A, Hill S, Gurung V, Prashar S, Smith AR. How accurate is symptomatic and clinical evaluation of prolapse prior to surgical repair? Int Urogynecol J Pelvic Floor Dysfunct. 2009;18(6):1179-83.

2. Fayyad A, Redhead E, Awan N, Kyrgiou M, Prashar S, Hill SR. Symptomatic and quality of life outcomes after site specific fascial reattachment for pelvic organ prolapse repair. Int Urogynecol J Pelvic Floor Dysfunct. 2009;19(9):191-7.

3. Haylen BT, de Ridder D, Freeman RM. An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J Pelvic Floor Dysfunct. 2010;21(1):5-26.

4. Sutherland S, Lavers A, Carlson A, Holtz C, Kesha J, Siegel S. Etiology of voiding dysfunction: one institution 11-year experience. Neurourol Urodyn. 2007;26:19-28.

5. Bump RC, Norton PA. Epidemiology and natural history of pelvic floor dysfunction. Obstet Gynecol Clin North Am. 2014;25(6):723-46.

6. Kessler T, Buchser E, Meyer S, Engeler D, Al-Kho A, Bersch U. Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland. Eur Urol. 2012;51:1357-63.

7. Finazzi-Agró E, Rocchi C, Pachatz C, Petta F, Spera E, Mori F, et al. Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials. Neurourol Urodyn. 2009;28(4):320-25.

8. Abosief S, Kim D, Rieder J, Rhee E, Meneffe S, Kaswick J, et al. Sacral neuromodulation: cost considerations and clinical benefits. Urology. 2007;70:1069-73.

9. Cundiff GW, Harris RL, Coates KW, Bump RC. Clinical predictors of urinary incontinence in women. Am J Obstet Gynecol. 1997;177(2):262-6.

10. Digesu GA, Khullar V, Cardozo L, Robinson D, Salvatore S. P-QOL: a validated questionnaire to assess the symptoms and quality of life of women with urogenital prolapsed. Int Urogynecol J Pelvic Floor Dysfunct. 2013;16(2):176-81.

11. Swift SE .The distribution of pelvic organ support in a population of female subjects seen for routine gynecologic health care. Am J Obstet Gynecol. 2011;183:277-85.

12. Samuelsson EC, Arne FT, Tibblin G, Svardsudd KF. Signs and treatment of genital prolapse in a swedish population of women 20-59 years of age and possible related factors. Am J Gynecol. 2013;180(8):299-305.

13. Liang CC, Tseng LH, Chang SD, Chang YL, Lo TS. Resolution of elevated postvoid residual volumes after correction of severe pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(9):1261-6.

14. Burrows L, Meyn L, Walters M, Weber A. Pelvic symptoms and treatment in women with pelvic organ prolapse. Obstet Gynecol. 2012;104(5):982-8.

15. Bradley C, Nygaard I, Initiative WH .Vaginal wall descensus and pelvic floor symptoms in older women. Obstet Gynecol. 2010;106(7):759-66.

16. Digesu GA, Khullar V, Cardozo L, Robinson D. Interobserver reliability of digital vaginal examination using a four grade scale in different patient positions. Int Urogynecol J Pelvic Floor Dysfunct. 2010;19(3):1303-7.

17. Srikrishna S, Robinson D, Cardozo L, Gonzalez J. Is there a difference in patient and physician quality of life evaluation in pelvic organ prolapse? Int Urogynecol J Pelvic Floor Dysfunct. 2011;19(9):517-20.

18. Digesu GA, Salvator S, Chaliha C, Athanasiou S, Milani R, Khullar V. Do overactive bladder symptoms improve after repair of anterior vaginal wall prolapse? Int Urogynecol J Pelvic Floor Dysfunct. 2011;18(8):1439-43.

19. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life after medical treatment of urinary incontinent in women. Br J Obstet Gynecol. 2014;104(7):1374-9.

20. Chai AH, Wong T, Mak HL, Cheon C, Yip SK, Wong AS. Prevalence and associated risk factors of retention of urine. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(4):537-42.

21. Kessler J, Baguley IJ. Urinary retention in a general rehabilitation unit: prevalence, clinical outcome, and the role of screening. Arch Phys Med Rehabil. 2014;86(9):1772-7.

22. Kessler SK, Sahota DS, Chang AM. A probability model for ultrasound estimation of bladder volume in the diagnosis of female urinary retention. Gynecol Obstet Invest. 2003;55(4):235-40.

23. Yip SK, Hin LY, Chung TK. Surgical treatment for pelvic organs prolapse. Gynecol Obstet Invest. 2011;45(3):177-80.